JP2022509448A5 - - Google Patents

Info

Publication number
JP2022509448A5
JP2022509448A5 JP2021547964A JP2021547964A JP2022509448A5 JP 2022509448 A5 JP2022509448 A5 JP 2022509448A5 JP 2021547964 A JP2021547964 A JP 2021547964A JP 2021547964 A JP2021547964 A JP 2021547964A JP 2022509448 A5 JP2022509448 A5 JP 2022509448A5
Authority
JP
Japan
Prior art keywords
cancer
atezolizumab
bevacizumab
resistant
signaling
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021547964A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022509448A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/058848 external-priority patent/WO2020089722A1/en
Publication of JP2022509448A publication Critical patent/JP2022509448A/ja
Publication of JP2022509448A5 publication Critical patent/JP2022509448A5/ja
Priority to JP2024213116A priority Critical patent/JP2025060639A/ja
Pending legal-status Critical Current

Links

JP2021547964A 2018-10-31 2019-10-17 Pd-1/pd-l1シグナル伝達阻害剤に不応答性のがんの処置方法および医薬 Pending JP2022509448A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024213116A JP2025060639A (ja) 2018-10-31 2024-12-06 Pd-1/pd-l1シグナル伝達阻害剤に不応答性のがんの処置方法および医薬

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018206076 2018-10-31
JP2018206076 2018-10-31
PCT/IB2019/058848 WO2020089722A1 (en) 2018-10-31 2019-10-17 Method and medicament for treating cancer unresponsive to pd-1/pd-l1 signaling inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024213116A Division JP2025060639A (ja) 2018-10-31 2024-12-06 Pd-1/pd-l1シグナル伝達阻害剤に不応答性のがんの処置方法および医薬

Publications (2)

Publication Number Publication Date
JP2022509448A JP2022509448A (ja) 2022-01-20
JP2022509448A5 true JP2022509448A5 (cg-RX-API-DMAC7.html) 2024-04-22

Family

ID=70463563

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021547964A Pending JP2022509448A (ja) 2018-10-31 2019-10-17 Pd-1/pd-l1シグナル伝達阻害剤に不応答性のがんの処置方法および医薬
JP2024213116A Pending JP2025060639A (ja) 2018-10-31 2024-12-06 Pd-1/pd-l1シグナル伝達阻害剤に不応答性のがんの処置方法および医薬

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024213116A Pending JP2025060639A (ja) 2018-10-31 2024-12-06 Pd-1/pd-l1シグナル伝達阻害剤に不応答性のがんの処置方法および医薬

Country Status (12)

Country Link
US (2) US12577307B2 (cg-RX-API-DMAC7.html)
EP (1) EP3873527A4 (cg-RX-API-DMAC7.html)
JP (2) JP2022509448A (cg-RX-API-DMAC7.html)
KR (1) KR20210084560A (cg-RX-API-DMAC7.html)
CN (1) CN114340679A (cg-RX-API-DMAC7.html)
AU (1) AU2019372239A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021008117A2 (cg-RX-API-DMAC7.html)
CA (1) CA3115798A1 (cg-RX-API-DMAC7.html)
IL (1) IL282654A (cg-RX-API-DMAC7.html)
MX (1) MX2021004709A (cg-RX-API-DMAC7.html)
TW (1) TW202031291A (cg-RX-API-DMAC7.html)
WO (1) WO2020089722A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106397592A (zh) * 2015-07-31 2017-02-15 苏州康宁杰瑞生物科技有限公司 针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白
JP7148037B2 (ja) 2018-12-03 2022-10-05 イミューンオンコ バイオファーマシューティカルズ (シャンハイ) インコーポレイテッド Pd-l1とvegfを標的化する組換えタンパク質
WO2022089377A1 (en) * 2020-10-26 2022-05-05 Taizhou Eoc Pharma Co., Ltd. Combination of a pd-1 or pd-l1 antagonist and a vegfr inhibitor for treating cancer
WO2023088436A1 (zh) * 2021-11-18 2023-05-25 信达生物制药(苏州)有限公司 抗pd-1抗体和抗vegf-a抗体的药物组合及其使用方法
TW202444368A (zh) * 2023-03-30 2024-11-16 瑞典商米迪維艾克提伯拉公司 以氟曲沙他濱布洛帕胺(fostroxacitabine bralpamide)、免疫檢查點抑制劑及vegf拮抗劑治療肝癌之方法
KR20260116273A (ko) 2024-09-20 2026-07-28 파라곤 테라퓨틱스, 인크. Pd-1 결합 단백질, vegf 및 pd-1 이중특이적 결합 단백질, 조성물 및 사용 방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
ES2763429T5 (es) 2013-12-17 2023-06-21 Hoffmann La Roche Procedimientos de tratamiento de cánceres usando antagonistas de la unión al eje de PD-1 y taxanos
US10570202B2 (en) 2014-02-04 2020-02-25 Pfizer Inc. Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer
RU2766890C2 (ru) 2015-06-16 2022-03-16 Мерк Патент Гмбх Комбинированные способы лечения антагонистами pd-l1
DK3858859T3 (da) 2015-07-14 2025-12-15 Bristol Myers Squibb Co Fremgangsmåde til behandling af kræft under anvendelse af en immun checkpointinhibitor; antistof som binder til programmeret død-1 receptor (pd-1) eller programmeret død ligand 1 (pd-l1)
CN106397592A (zh) 2015-07-31 2017-02-15 苏州康宁杰瑞生物科技有限公司 针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白
MX2019010295A (es) 2017-03-01 2019-11-21 Genentech Inc Métodos de diagnóstico y terapéuticos para el cáncer.

Similar Documents

Publication Publication Date Title
Doebele et al. Phase 2, randomized, open‐label study of ramucirumab in combination with first‐line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non–small cell lung cancer
Choi et al. Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma
Bose et al. Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care
Dorta-Estremera et al. Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV+ oral cancer
Fan et al. Systemic therapy for hepatocellular carcinoma: current updates and outlook
Aghajanian et al. Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer
Kim et al. A phase II study of pembrolizumab and paclitaxel in patients with relapsed or refractory small-cell lung cancer
Rougier et al. Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer
Crombet Ramos et al. Nimotuzumab for patients with inoperable cancer of the head and neck
Jensen et al. Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer
Zhou et al. Phase III trials of standard chemotherapy with or without bevacizumab for ovarian cancer: a meta-analysis
Ruzsa et al. Phase 2, open-label, 1: 1 randomized controlled trial exploring the efficacy of EMD 1201081 in combination with cetuximab in second-line cetuximab-naïve patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)
Petrelli et al. Correlation of progression-free and post-progression survival with overall survival in advanced colorectal cancer
JP2016540042A5 (cg-RX-API-DMAC7.html)
MX2020006042A (es) Metodos de tratamiento de cancer de colon usando terapia combinada de inhibidor del objetivo mamifero de la rapamicina (mtor) en nanoparticulas.
JP2016520528A5 (cg-RX-API-DMAC7.html)
Kerbel Strategies for improving the clinical benefit of antiangiogenic drug based therapies for breast cancer
JP2019532047A5 (cg-RX-API-DMAC7.html)
Petrillo et al. Biomarkers for precision treatment in gastric cancer
Lee et al. Clinical and cost effectiveness of bevacizumab+ FOLFIRI combination versus FOLFIRI alone as first-line treatment of metastatic colorectal cancer in South Korea
Xu et al. Leveraging the synergy between anti-angiogenic therapy and immune checkpoint inhibitors to treat digestive system cancers
Kirstein et al. Sequential systemic treatment in patients with hepatocellular carcinoma
Khadela et al. A review of efficacy and safety of cetuximab and bevacizumab-based monoclonal antibodies in head and neck cancer
Taketomi Clinical trials of antiangiogenic therapy for hepatocellular carcinoma
Rallis et al. Immunotherapy for advanced hepatocellular carcinoma: From clinical trials to real-world data and future advances